Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasm Recurrence, Local | 14 | 2020 | 9273 | 0.460 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 14 | 2020 | 11709 | 0.430 |
Why?
|
HIV-1 | 10 | 2023 | 6850 | 0.370 |
Why?
|
Androgen Antagonists | 5 | 2018 | 1442 | 0.330 |
Why?
|
Models, Statistical | 3 | 2008 | 5070 | 0.320 |
Why?
|
Carcinoma, Renal Cell | 6 | 2019 | 3217 | 0.290 |
Why?
|
HIV Seropositivity | 2 | 2023 | 960 | 0.280 |
Why?
|
Prostatic Neoplasms | 10 | 2018 | 11336 | 0.260 |
Why?
|
Patient Dropouts | 1 | 2008 | 412 | 0.260 |
Why?
|
Aromatase | 2 | 2016 | 147 | 0.250 |
Why?
|
Breast Neoplasms | 11 | 2020 | 21017 | 0.230 |
Why?
|
Nitriles | 4 | 2020 | 957 | 0.220 |
Why?
|
Disease-Free Survival | 6 | 2019 | 6821 | 0.220 |
Why?
|
HIV Infections | 12 | 2023 | 17275 | 0.220 |
Why?
|
Survival Analysis | 7 | 2019 | 10112 | 0.220 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2020 | 567 | 0.210 |
Why?
|
Receptors, Estrogen | 4 | 2020 | 2211 | 0.210 |
Why?
|
PTEN Phosphohydrolase | 2 | 2018 | 1113 | 0.210 |
Why?
|
Kaplan-Meier Estimate | 12 | 2020 | 6493 | 0.210 |
Why?
|
Receptors, Androgen | 2 | 2020 | 1078 | 0.200 |
Why?
|
Estrogen Receptor alpha | 2 | 2016 | 580 | 0.200 |
Why?
|
Cytidine Deaminase | 2 | 2014 | 245 | 0.190 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 1086 | 0.190 |
Why?
|
Ritonavir | 2 | 2008 | 328 | 0.190 |
Why?
|
Tamoxifen | 3 | 2016 | 963 | 0.190 |
Why?
|
Lead Poisoning | 1 | 2023 | 321 | 0.180 |
Why?
|
Viral Load | 6 | 2008 | 3321 | 0.180 |
Why?
|
Antineoplastic Agents, Hormonal | 5 | 2018 | 1530 | 0.180 |
Why?
|
Central Nervous System Diseases | 3 | 2013 | 520 | 0.170 |
Why?
|
HIV Integrase Inhibitors | 1 | 2022 | 165 | 0.170 |
Why?
|
Anti-HIV Agents | 4 | 2023 | 4504 | 0.160 |
Why?
|
Triazoles | 2 | 2015 | 902 | 0.160 |
Why?
|
Neoplasm Metastasis | 6 | 2019 | 4901 | 0.150 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2018 | 101 | 0.150 |
Why?
|
HIV Protease Inhibitors | 3 | 2008 | 432 | 0.150 |
Why?
|
RNA, Viral | 6 | 2023 | 2836 | 0.150 |
Why?
|
Lead | 1 | 2023 | 878 | 0.150 |
Why?
|
Testicular Neoplasms | 2 | 2014 | 801 | 0.150 |
Why?
|
Radium | 1 | 2018 | 72 | 0.150 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2007 | 1895 | 0.150 |
Why?
|
Kidney Neoplasms | 3 | 2019 | 4312 | 0.150 |
Why?
|
Mannose-Binding Lectin | 1 | 2008 | 146 | 0.140 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2017 | 122 | 0.140 |
Why?
|
Gene Fusion | 1 | 2019 | 354 | 0.140 |
Why?
|
Bone Diseases | 1 | 2020 | 419 | 0.140 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2016 | 10146 | 0.140 |
Why?
|
Reverse Transcriptase Inhibitors | 2 | 2004 | 619 | 0.130 |
Why?
|
Secretory Leukocyte Peptidase Inhibitor | 1 | 2016 | 23 | 0.130 |
Why?
|
DNA Mismatch Repair | 1 | 2019 | 428 | 0.130 |
Why?
|
Data Interpretation, Statistical | 1 | 2006 | 2690 | 0.130 |
Why?
|
Cancer Care Facilities | 1 | 2019 | 424 | 0.130 |
Why?
|
Postmenopause | 3 | 2020 | 2509 | 0.130 |
Why?
|
Taxoids | 2 | 2019 | 668 | 0.130 |
Why?
|
Colonic Polyps | 1 | 2020 | 551 | 0.130 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2019 | 479 | 0.120 |
Why?
|
Ovary | 2 | 2018 | 958 | 0.120 |
Why?
|
Chemotherapy, Adjuvant | 7 | 2018 | 3527 | 0.120 |
Why?
|
Estrogen Receptor beta | 1 | 2015 | 168 | 0.120 |
Why?
|
Mortality | 1 | 2006 | 2885 | 0.120 |
Why?
|
Receptors, Progesterone | 2 | 2018 | 1130 | 0.120 |
Why?
|
Middle Aged | 35 | 2020 | 219560 | 0.110 |
Why?
|
Cyclophosphamide | 2 | 2016 | 2218 | 0.110 |
Why?
|
Insulin-Like Growth Factor Binding Protein 1 | 1 | 2013 | 125 | 0.110 |
Why?
|
Bone Density Conservation Agents | 1 | 2020 | 794 | 0.110 |
Why?
|
Prostatectomy | 2 | 2018 | 1956 | 0.110 |
Why?
|
Dideoxynucleosides | 1 | 2003 | 131 | 0.110 |
Why?
|
Methotrexate | 2 | 2016 | 1719 | 0.100 |
Why?
|
Seminoma | 1 | 2013 | 134 | 0.100 |
Why?
|
Colonoscopy | 1 | 2020 | 1388 | 0.100 |
Why?
|
Neoplasm Staging | 8 | 2019 | 11152 | 0.100 |
Why?
|
Prognosis | 12 | 2020 | 29558 | 0.100 |
Why?
|
Orchiectomy | 2 | 2014 | 470 | 0.100 |
Why?
|
Tablets | 2 | 2023 | 147 | 0.100 |
Why?
|
Aged | 27 | 2020 | 168217 | 0.100 |
Why?
|
Pyridones | 3 | 2023 | 785 | 0.100 |
Why?
|
Humans | 58 | 2024 | 758381 | 0.100 |
Why?
|
Prostate-Specific Antigen | 6 | 2019 | 2528 | 0.100 |
Why?
|
Chemokine CCL2 | 1 | 2014 | 604 | 0.100 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2014 | 329 | 0.090 |
Why?
|
Interleukin-8 | 1 | 2014 | 696 | 0.090 |
Why?
|
Female | 37 | 2024 | 390316 | 0.090 |
Why?
|
Androgens | 2 | 2016 | 1291 | 0.090 |
Why?
|
Prostate | 1 | 2018 | 1791 | 0.090 |
Why?
|
Alleles | 4 | 2015 | 6895 | 0.090 |
Why?
|
Endometrial Neoplasms | 1 | 2019 | 1357 | 0.090 |
Why?
|
Adenoma | 1 | 2020 | 2148 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2020 | 15773 | 0.090 |
Why?
|
Survival Rate | 6 | 2020 | 12721 | 0.080 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2014 | 494 | 0.080 |
Why?
|
Male | 34 | 2024 | 358742 | 0.080 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2018 | 1888 | 0.080 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2013 | 675 | 0.080 |
Why?
|
Estrogens | 1 | 2016 | 1520 | 0.080 |
Why?
|
Phenylthiohydantoin | 2 | 2020 | 204 | 0.080 |
Why?
|
Pyrones | 1 | 2008 | 35 | 0.080 |
Why?
|
Sarcoma | 1 | 2019 | 1785 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 2912 | 0.080 |
Why?
|
Mutation | 5 | 2020 | 29915 | 0.070 |
Why?
|
Disease Progression | 6 | 2019 | 13468 | 0.070 |
Why?
|
Adenocarcinoma | 2 | 2015 | 6313 | 0.070 |
Why?
|
Adult | 21 | 2024 | 219916 | 0.070 |
Why?
|
Aged, 80 and over | 12 | 2020 | 58681 | 0.070 |
Why?
|
HIV | 1 | 2004 | 1581 | 0.070 |
Why?
|
Polyethylene Glycols | 1 | 2013 | 1188 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3480 | 0.070 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2019 | 2016 | 0.070 |
Why?
|
Treatment Outcome | 13 | 2020 | 64379 | 0.070 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2016 | 2057 | 0.070 |
Why?
|
CD4 Lymphocyte Count | 4 | 2007 | 2569 | 0.070 |
Why?
|
Doxorubicin | 1 | 2013 | 2209 | 0.070 |
Why?
|
Follow-Up Studies | 8 | 2020 | 39060 | 0.070 |
Why?
|
Genotype | 6 | 2018 | 12945 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2018 | 2531 | 0.060 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 2800 | 0.060 |
Why?
|
Tumor Burden | 3 | 2018 | 1893 | 0.060 |
Why?
|
HLA Antigens | 1 | 2011 | 1368 | 0.060 |
Why?
|
Likelihood Functions | 1 | 2008 | 987 | 0.060 |
Why?
|
Infant | 7 | 2024 | 36054 | 0.060 |
Why?
|
Endpoint Determination | 1 | 2008 | 590 | 0.060 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2004 | 2197 | 0.060 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12440 | 0.060 |
Why?
|
Benzamides | 2 | 2020 | 1368 | 0.060 |
Why?
|
Mass Screening | 1 | 2020 | 5425 | 0.060 |
Why?
|
Didanosine | 1 | 2004 | 151 | 0.060 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2004 | 110 | 0.060 |
Why?
|
Time Factors | 8 | 2019 | 39873 | 0.060 |
Why?
|
Adolescent | 12 | 2023 | 87888 | 0.060 |
Why?
|
Computer Simulation | 2 | 2008 | 6201 | 0.060 |
Why?
|
Antineoplastic Agents | 5 | 2020 | 13591 | 0.060 |
Why?
|
Child | 10 | 2024 | 79813 | 0.060 |
Why?
|
Child, Preschool | 7 | 2024 | 42058 | 0.060 |
Why?
|
Hot Flashes | 2 | 2016 | 328 | 0.050 |
Why?
|
Hydroxyurea | 1 | 2004 | 282 | 0.050 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2717 | 0.050 |
Why?
|
Indinavir | 1 | 2003 | 73 | 0.050 |
Why?
|
Rifabutin | 1 | 2003 | 58 | 0.050 |
Why?
|
Statistics, Nonparametric | 1 | 2008 | 2850 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2014 | 3485 | 0.050 |
Why?
|
Ovarian Neoplasms | 1 | 2019 | 4876 | 0.050 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2014 | 4342 | 0.050 |
Why?
|
Retrospective Studies | 11 | 2023 | 80170 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2019 | 9160 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2016 | 851 | 0.050 |
Why?
|
Lamivudine | 1 | 2023 | 362 | 0.050 |
Why?
|
Genetic Variation | 1 | 2016 | 6548 | 0.050 |
Why?
|
Risk Factors | 8 | 2020 | 73806 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6852 | 0.050 |
Why?
|
Poland | 1 | 2020 | 196 | 0.040 |
Why?
|
Piperazines | 2 | 2022 | 2511 | 0.040 |
Why?
|
Austria | 1 | 2020 | 206 | 0.040 |
Why?
|
Estradiol | 2 | 2018 | 1933 | 0.040 |
Why?
|
Feasibility Studies | 2 | 2023 | 5199 | 0.040 |
Why?
|
Drug Administration Schedule | 3 | 2019 | 4839 | 0.040 |
Why?
|
Oxazines | 1 | 2022 | 341 | 0.040 |
Why?
|
Combined Modality Therapy | 3 | 2018 | 8530 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2017 | 8506 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2016 | 5629 | 0.040 |
Why?
|
Odds Ratio | 3 | 2018 | 9650 | 0.040 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2022 | 278 | 0.040 |
Why?
|
Aging | 1 | 2008 | 8651 | 0.040 |
Why?
|
Diamines | 1 | 2019 | 59 | 0.040 |
Why?
|
Logistic Models | 3 | 2023 | 13276 | 0.040 |
Why?
|
Health Literacy | 1 | 2024 | 441 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2019 | 326 | 0.040 |
Why?
|
Cohort Studies | 6 | 2019 | 41252 | 0.040 |
Why?
|
Drug Therapy, Combination | 4 | 2008 | 6293 | 0.040 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2019 | 256 | 0.040 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 14641 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3615 | 0.040 |
Why?
|
Young Adult | 6 | 2023 | 58808 | 0.040 |
Why?
|
Phthalazines | 1 | 2019 | 382 | 0.040 |
Why?
|
Radioisotopes | 1 | 2018 | 495 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2018 | 551 | 0.030 |
Why?
|
Incidence | 2 | 2020 | 21273 | 0.030 |
Why?
|
Anthracyclines | 1 | 2019 | 282 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2019 | 778 | 0.030 |
Why?
|
Pyrimidinones | 1 | 2019 | 383 | 0.030 |
Why?
|
Pyridines | 1 | 2008 | 2860 | 0.030 |
Why?
|
Morpholines | 1 | 2019 | 580 | 0.030 |
Why?
|
Indazoles | 1 | 2018 | 302 | 0.030 |
Why?
|
Medical Oncology | 1 | 2008 | 2312 | 0.030 |
Why?
|
Lymphatic Metastasis | 2 | 2014 | 2943 | 0.030 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2018 | 412 | 0.030 |
Why?
|
Aminopyridines | 1 | 2019 | 564 | 0.030 |
Why?
|
Sweating | 1 | 2016 | 154 | 0.030 |
Why?
|
Risk Assessment | 4 | 2020 | 23883 | 0.030 |
Why?
|
Drug Synergism | 1 | 2019 | 1745 | 0.030 |
Why?
|
Hospitals, Pediatric | 1 | 2024 | 1854 | 0.030 |
Why?
|
Up-Regulation | 2 | 2014 | 4114 | 0.030 |
Why?
|
Estrone | 1 | 2016 | 232 | 0.030 |
Why?
|
Body Mass Index | 1 | 2012 | 12876 | 0.030 |
Why?
|
Software | 1 | 2008 | 4416 | 0.030 |
Why?
|
Premenopause | 1 | 2018 | 1038 | 0.030 |
Why?
|
Bone Remodeling | 1 | 2018 | 579 | 0.030 |
Why?
|
Sulfonamides | 2 | 2018 | 1973 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2018 | 1055 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2018 | 2470 | 0.030 |
Why?
|
Androstadienes | 1 | 2016 | 348 | 0.030 |
Why?
|
Chromosome Aberrations | 1 | 2020 | 1764 | 0.030 |
Why?
|
Follicle Stimulating Hormone | 1 | 2016 | 725 | 0.030 |
Why?
|
Family | 1 | 2024 | 3188 | 0.030 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2014 | 293 | 0.030 |
Why?
|
Luteinizing Hormone | 1 | 2016 | 820 | 0.030 |
Why?
|
Oligopeptides | 1 | 2018 | 1185 | 0.030 |
Why?
|
Anti-Retroviral Agents | 1 | 2023 | 1780 | 0.030 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2018 | 1153 | 0.030 |
Why?
|
Estrogen Receptor Modulators | 1 | 2012 | 58 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2019 | 9405 | 0.030 |
Why?
|
Colon | 1 | 2020 | 1788 | 0.030 |
Why?
|
Registries | 2 | 2019 | 8176 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2019 | 1611 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2716 | 0.020 |
Why?
|
Research Design | 1 | 2008 | 6154 | 0.020 |
Why?
|
Early Detection of Cancer | 2 | 2017 | 3211 | 0.020 |
Why?
|
Haplotypes | 1 | 2008 | 2764 | 0.020 |
Why?
|
Microarray Analysis | 1 | 2014 | 746 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2014 | 20500 | 0.020 |
Why?
|
Parents | 1 | 2024 | 3548 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2019 | 2443 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 1745 | 0.020 |
Why?
|
Obesity | 1 | 2012 | 12870 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2017 | 16886 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2016 | 1753 | 0.020 |
Why?
|
Signal Transduction | 3 | 2019 | 23341 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15225 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3056 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4106 | 0.020 |
Why?
|
Metabolic Diseases | 1 | 2016 | 682 | 0.020 |
Why?
|
Virus Replication | 1 | 2007 | 2430 | 0.020 |
Why?
|
Liposomes | 1 | 2013 | 777 | 0.020 |
Why?
|
Pyrazoles | 1 | 2019 | 1990 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2019 | 2980 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1651 | 0.020 |
Why?
|
Aromatase Inhibitors | 1 | 2012 | 511 | 0.020 |
Why?
|
Risk-Taking | 1 | 2004 | 1034 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2020 | 17768 | 0.020 |
Why?
|
Adiponectin | 1 | 2013 | 1114 | 0.020 |
Why?
|
Mastectomy, Segmental | 1 | 2013 | 972 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2018 | 2821 | 0.020 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2014 | 1214 | 0.020 |
Why?
|
Algorithms | 1 | 2008 | 13959 | 0.020 |
Why?
|
Lymph Node Excision | 1 | 2013 | 1303 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2018 | 22031 | 0.020 |
Why?
|
Nephrectomy | 1 | 2012 | 1016 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2015 | 12262 | 0.020 |
Why?
|
United States | 3 | 2020 | 72140 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10747 | 0.020 |
Why?
|
Pyrimidines | 1 | 2018 | 3006 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11070 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5781 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2008 | 604 | 0.020 |
Why?
|
Leptin | 1 | 2013 | 1591 | 0.020 |
Why?
|
Computational Biology | 1 | 2017 | 3502 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2023 | 5403 | 0.020 |
Why?
|
Blood Coagulation Disorders | 1 | 2008 | 349 | 0.020 |
Why?
|
Vomiting | 1 | 2008 | 651 | 0.020 |
Why?
|
Quality of Life | 2 | 2019 | 13286 | 0.020 |
Why?
|
Clinical Competence | 1 | 2020 | 4775 | 0.020 |
Why?
|
Genomics | 1 | 2020 | 5789 | 0.010 |
Why?
|
Prospective Studies | 2 | 2019 | 54136 | 0.010 |
Why?
|
Mastectomy | 1 | 2013 | 1832 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2003 | 7403 | 0.010 |
Why?
|
Regression Analysis | 1 | 2004 | 6353 | 0.010 |
Why?
|
DNA, Viral | 1 | 2011 | 2194 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8611 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2008 | 13245 | 0.010 |
Why?
|
Pain | 1 | 2018 | 5065 | 0.010 |
Why?
|
Recurrence | 1 | 2014 | 8426 | 0.010 |
Why?
|
Models, Biological | 1 | 2018 | 9461 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14354 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2011 | 6068 | 0.010 |
Why?
|
Diarrhea | 1 | 2008 | 1317 | 0.010 |
Why?
|
Cognition | 1 | 2008 | 6955 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2016 | 10417 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12096 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2014 | 12760 | 0.010 |
Why?
|
Area Under Curve | 1 | 2003 | 1632 | 0.010 |
Why?
|
Drug Interactions | 1 | 2003 | 1414 | 0.010 |
Why?
|
Comorbidity | 1 | 2013 | 10495 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 12604 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 2003 | 2048 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2007 | 26182 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 20052 | 0.010 |
Why?
|
Mice | 1 | 2017 | 81107 | 0.010 |
Why?
|
Animals | 1 | 2017 | 167777 | 0.000 |
Why?
|